Compare ConocoPhillips (COP) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ConocoPhillips vs TransMedics Group Inc — how do they compare? ConocoPhillips trades at $133.26 (market cap $161.21B), while TransMedics Group Inc trades at $79.01 (market cap $2.74B). The key difference: ConocoPhillips is far larger — about 58.8× TransMedics Group Inc's market cap, and ConocoPhillips pays a 2.5% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold ConocoPhillips for 79 Days and TransMedics Group Inc for 24 Days on average.
| COP | TMDX | |
|---|---|---|
Market Cap | $161.21B | $2.74B |
Volume | 6,058,403 | 949,331 |
Sector | Energy | Health |
52-Week High | $141.22 | $150.42 |
52-Week Low | $85.66 | $61.99 |
Typical Hold Time | 79 Days | 24 Days |
Enterprise Value | $176.81B | $3.13B |
Dividend Yield | 2.5% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ConocoPhillips (COP) trades at $129.84, up 0.38% today, with strong technical momentum and bullish moving average signals. The company reported mixed Q4 2025 earnings but beat expectations in Q1 and Q2 2026, with revenue growth from $58.94B in 2025 to projected $63.3B in 2026. Recent developments include a 20-year LNG supply agreement with Venture Global and potential asset sales in Norway and the UK, signaling strategic portfolio optimization.
COP presents a compelling investment case with solid fundamentals—P/E of 17.75, ROE of 14.14%, and robust cash flow—supported by a 75% analyst buy rating and $154.75 consensus price target. Key risks include geopolitical exposure in the Middle East, oil price volatility, and execution of asset sales. The stock's current level near resistance at $130 suggests near-term consolidation potential amid bullish long-term prospects.
TMDX trades at $81.07, up 0.98% today, but faces a bearish technical signal with recent price weakness. Fundamentally, the company reported strong 2025 results with $605.49M revenue and $190.29M net income, though 2026 projections show margin compression. Recent news highlights insider buying and ongoing legal investigations into fiduciary duties, creating mixed sentiment.
The stock offers potential upside to the $99.75 consensus target, supported by a 69% buy rating from analysts, but risks include earnings misses, margin pressure from heavy investment, and legal overhangs. Execution on growth amid rising costs remains critical for sustaining its premium valuation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ConocoPhillips
ConocoPhillips is a U.S.-based independent exploration and production firm. In 2021, it produced 1.0 million barrels per day of oil and natural gas liquids and 3.2 billion cubic feet per day of natural gas, primarily from Alaska and the Lower 48 in the United States and Norway in Europe and several countries in Asia-Pacific and the Middle East. Proven reserves at year-end 2021 were 6.1 billion barrels of oil equivalent.
Read more on COP →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
